Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME and Absolute Bioavailability of Ervogastat in Healthy Men
NCT04866225Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ervogastat in Nonalcoholic steatohepatitis (NASH), sponsored by Pfizer. Primary endpoints: Total Recovery of Radioactivity in Urine, Total Recovery of Radioactivity in Feces and 2 more. Started May 2021; status: completed.
02
Drugs
ervogastat
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04866225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04866225.